PPARA and hyperlipidemia: Previous studies have shown that loss of peroxisome proliferator-activated receptor alpha (PPARα) in the liver results in inflammation and hyperlipidemia in response to HFD (44, 45), and PPARα agonists are approved for the treatment of dyslipidemia (54).